TSN1611 / Tyligand - LARVOL DELTA

Updated results of the phase 1/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors. (ASCO-GI 2026) - P1/2 | "Funded by Tyligand Pharmaceuticals (Suzhou) Limited Clinical Trial Registration Number: NCT06385925 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Metastases • P1/2 data • Gastrointestinal Cancer • Oncology • Solid Tumor • KRAS

The first-in-human phase 1/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors. (ASCO 2025) - P1/2 | "TSN1611 was well tolerated, demonstrating acceptable PK characteristics as predicted, with preliminary tumor shrinkage observed in pts with refractory KRAS G12D mutant tumors. Phase 1b/2 studies are planned to evaluate TSN1611 both as a monotherapy and in combination with standard of care and/or novel agents treating cancer."

Clinical • Metastases • P1/2 data • Ampulla of Vater Carcinoma • Colorectal Cancer • Fatigue • Gallbladder Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS

Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a Selective and Orally Bioavailable KRAS G12D Inhibitor (PRNewswire) - "Tyligand Bioscience...announced that the first patient had been dosed in the Phase 1/2 trial of TSN1611 for the treatment of KRAS G12D mutant solid tumors in the United States....Patient recruitment is currently underway in the United States, with plans to initiate in China in the coming months."

Trial status • Solid Tumor

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation (clinicaltrials.gov) - P1/2 | N=150 | Recruiting | Sponsor: Tyligand Bioscience (Shanghai) Limited

Metastases • New P1/2 trial • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS

Preclinical studies of TSN1611, a potent, selective, and orally bioavailable KRASG12D inhibitor (AACR 2024) - "TSN1611 is a selective KRASG12D inhibitor. It exhibited excellent selectivity and activity both in vitro and in vivo; it demonstrated favorable physicochemical properties, oral PK profiles, and brain penetration potential; it also showed acceptable margins of safety. The preclinical data supports further development."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • HRAS • KRAS • NRAS